Why Vitamin D Deficiency Is a Hidden Concern for Women Taking Anastrozole

For many women navigating anastrozole therapy, the conversation about bone health centers almost exclusively on calcium supplements and periodic DEXA scans. What often goes unaddressed—and what emerging evidence suggests deserves far more attention—is the role that vitamin D plays in the overall picture. Vitamin D deficiency is common in the general US population, but women on aromatase inhibitor therapy face a compounded set of circumstances that make routine testing not just reasonable, but arguably essential.

The Baseline Problem: Vitamin D Deficiency Is Already Widespread

Before examining how anastrozole specifically intersects with vitamin D status, it helps to understand how prevalent deficiency already is. According to data from the National Health and Nutrition Examination Survey (NHANES), approximately 41 percent of US adults have insufficient vitamin D levels, with deficiency rates considerably higher among older women, individuals with darker skin tones, and those who live in northern latitudes with limited sun exposure during winter months.

Postmenopausal women—the population most commonly prescribed anastrozole—tend to synthesize vitamin D less efficiently through sun exposure than younger individuals. Add to that the reality that many women newly diagnosed with breast cancer have been spending less time outdoors, are managing fatigue, or are simply not eating with optimal nutrition in mind, and the stage is set for deficiency even before treatment begins.

How Anastrozole Therapy Changes the Equation

Anastrozole works by suppressing the aromatase enzyme, dramatically reducing circulating estrogen in postmenopausal women. This mechanism is precisely why it is effective against hormone receptor-positive breast cancer. However, estrogen plays a protective role in bone metabolism, and its suppression accelerates bone mineral density loss—a well-documented side effect that typically begins within the first year of therapy.

Vitamin D is indispensable to this equation because it is required for calcium absorption in the gut and for maintaining the bone remodeling cycle. Without adequate vitamin D, calcium supplementation is far less effective. The two nutrients work in concert, and deficiency in one undermines the benefit of the other.

Beyond bone health, some research suggests that the metabolic pathways involved in aromatase inhibitor therapy may interact with vitamin D metabolism more directly. Estrogen influences the expression of enzymes involved in converting vitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol). When estrogen levels fall sharply—as they do during anastrozole therapy—this conversion process may become less efficient, potentially contributing to lower active vitamin D availability even when dietary intake appears adequate.

While this area of research is still developing, several clinical studies have observed that women on aromatase inhibitors tend to have lower vitamin D levels compared with breast cancer patients not receiving hormonal therapy, even when other variables are controlled.

What the Research Says About Testing and Outcomes

A number of oncology guidelines, including those from the American Society of Clinical Oncology (ASCO), recommend that women starting aromatase inhibitor therapy have their vitamin D status assessed, particularly in the context of bone health monitoring. The standard test is a serum 25-hydroxyvitamin D measurement, and most clinicians consider levels below 20 ng/mL to be deficient, with levels between 20 and 30 ng/mL generally categorized as insufficient.

Clinical trials examining vitamin D supplementation in AI patients have reported encouraging findings. One frequently cited study found that women who corrected vitamin D deficiency prior to or during aromatase inhibitor therapy experienced less severe musculoskeletal pain—one of the most common and treatment-limiting side effects of anastrozole. Joint pain and muscle aches affect a significant proportion of women on aromatase inhibitors, and while the mechanism is not fully understood, inflammation and altered nerve sensitivity in connective tissue are believed to be involved. Vitamin D has established anti-inflammatory properties, and its deficiency has been independently associated with musculoskeletal discomfort.

Beyond musculoskeletal effects, adequate vitamin D levels are associated with better immune regulation and have been explored in the context of cancer outcomes more broadly. While the evidence linking vitamin D supplementation to cancer recurrence reduction remains inconclusive and should not be overstated, the systemic benefits of correcting a deficiency during a demanding treatment period are well-supported.

Practical Guidance: What to Ask and What to Expect

If your oncologist has not yet ordered a vitamin D level as part of your anastrozole monitoring, this is a straightforward and appropriate question to raise at your next appointment. Ask specifically for a serum 25-hydroxyvitamin D test, and request that the result be shared with you along with a clear explanation of where your level falls relative to clinical thresholds.

If deficiency is confirmed, your care team will likely recommend supplementation. Vitamin D3 (cholecalciferol) is the preferred form for most patients, as it is more effective than D2 at raising serum levels. Dosing will depend on the severity of your deficiency, but supplementation in the range of 1,000 to 4,000 IU daily is common, with higher loading doses sometimes prescribed under physician supervision for significant deficiency.

Importantly, vitamin D supplementation at standard doses does not interfere with anastrozole's mechanism of action or its efficacy against hormone receptor-positive breast cancer. There is no evidence that correcting vitamin D deficiency diminishes the drug's effectiveness, and patients should feel reassured on this point. The same cannot be said for all supplements—some have documented interactions with anastrozole or with estrogenic activity—but vitamin D is not among them.

Monitoring and Ongoing Assessment

Vitamin D status is not a one-time measurement. Levels fluctuate with season, sun exposure, dietary changes, and supplementation adherence. For women on a multi-year course of anastrozole—which is standard for many hormone receptor-positive breast cancer patients—periodic retesting makes clinical sense. Many oncologists incorporate this into annual blood work alongside bone density monitoring and other standard assessments.

Keep in mind that very high vitamin D levels can cause toxicity, primarily through hypercalcemia. This is rare with supplementation doses in the standard therapeutic range but reinforces the importance of testing rather than self-directing high-dose supplementation without medical oversight. More is not always better, and the goal is to achieve and maintain a level that supports bone health and overall physiological function—not to maximize the number on a lab report.

A Conversation Worth Having

Anastrozole therapy demands a great deal from the body over months and years of treatment. Supporting that process with thorough nutritional monitoring is not a peripheral concern—it is part of comprehensive cancer care. Vitamin D testing is inexpensive, widely available, and easily incorporated into routine oncology follow-up. If it has not yet been part of your care plan, it is entirely reasonable to bring it forward as a priority.

Your oncologist is your primary resource for interpreting results and recommending appropriate supplementation, but being an informed and engaged participant in that conversation is one of the most effective tools available to you during treatment.